Skip to main content
profileAnalyst coverage5 yr. financialspremium researchdividendsadv. chartsearningsoptionsprice historyeventsinsiders

n.a. News

Clovis Spikes on Phase 3 Data for Ovarian Cancer Drug - Biotech Movers - Biotech Movers

The company is scheduled Friday afternoon to present comprehensive data from its Phase 3 study of rucaparib at the European Society for Medical Oncology Congress in Madrid.

Biotech Movers: Cesca Up Strong After Securing CAR-T Cell Patent

And a management shakeup helps push down NuVasive.

Biotech Movers: NewLink, Inovio, Juno

NewLink Genetics, Inovio Pharmaceuticals and Juno Therapeutics were among the biotech stock movers in premarket trading on Thursday.

Biotech Movers: Loxo, NewLink, BioCryst

Loxo Oncology, NewLink Genetics and BioCryst Pharmaceuticals were among the biotech movers in premarket trading on Monday.

Incyte Shares Jump After 'IDO' Cancer Immunotherapy Combo Data Revealed

The new Incyte data revealed ahead of the ASCO meeting in June involve combination therapies with Merck and Bristol-Myers Squibb in multiple types of cancer.

Breaking News

Morgan Stanley Stock Leads Gains As Banks Boost Dividends After Fed Stress Tests

Morgan Stanley, Wells Fargo, Bank of America and Goldman Sachs will lift their quarterly dividend, while JPMorgan will hold its steady following last week's Fed stress tests.

Nike Stock Slides As As Margin Pressures, China Worries Offset Q4 Earnings Beat

"We think we're well positioned for growth in fiscal year 2023 ... having said that, we did take a cautious approach to Greater China," said CFO Matthew Friend.

Stocks Higher, Bank Dividends, Nike, Playtika And Occidental- Five Things To Know

Stock futures higher on global growth bets; Morgan Stanley leads bank gains after dividend boost; Nike slides as margin pressures offset Q4 earnings beat; Playtika shares surge on report of Joffre Capital interest and Occidental shares jump as Buffett adds more to stake

Walgreens Stock Slides As Group Scraps Plan to Sell UK-based Boots

"As a result of market instability ... no third party has been able to make an offer that adequately reflects the high potential value of Boots," Walgreens said.